

Product Datasheet

STX-478

Catalog No. **BP-02252** · CAS **2883540-92-7** · Form **free base** · Physical state **other** · Color **White to off-white** · Version **1.0** · Revision **2026-09-03**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target PI3K	Research area Cancer
-----------------------	--------------------------------

Molecular formula **C₁₆H₁₂F₅N₅O₂**

Molecular weight **401.2908**

STRUCTURE



DESCRIPTION

STX-478 (compound 80) is an oral CNS-penetrant allosteric mutant-selective PI3K α inhibitor. STX-478 shows robust and durable tumor regression and can be used in cancer research.

BIOLOGICAL ACTIVITY

STX-478 (0-10,000 nM; 1 h) demonstrates selectivity for MCF10A cells harboring the H1047R kinase-domain mutation. STX-478 (30, 100 mg/kg; p.o.; single daily for 28 days) dose-dependently reduces tumor volume in a CAL-33 xenograft mice model.

SOLUBILITY

Soluble in DMSO

In vitro DMSO : 100 mg/mL

REFERENCES

[1]. JR David St Jean, et al. Urea derivatives which can be used to treat cancer. Patent WO2022265993A1.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.